IBB vs. EEMA
IBB (iShares Nasdaq Biotechnology ETF) and EEMA (iShares MSCI Emerging Markets Asia ETF) are both exchange-traded funds - IBB is a Health & Biotech Equities fund tracking the NASDAQ Biotechnology Index, while EEMA is a Asia Pacific Equities fund tracking the MSCI Emerging Markets Asia Index. Both are passively managed. Over the past 10 years, IBB returned 7.19%/yr vs 10.78%/yr for EEMA. At a 0.44 correlation, their price movements are largely independent. IBB charges 0.47%/yr vs 0.50%/yr for EEMA.
Performance
IBB vs. EEMA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, IBB achieves a 1.19% return, which is significantly lower than EEMA's 23.70% return. Over the past 10 years, IBB has underperformed EEMA with an annualized return of 7.19%, while EEMA has yielded a comparatively higher 10.78% annualized return.
IBB
- 1D
- 0.10%
- 1M
- -1.15%
- YTD
- 1.19%
- 6M
- 0.91%
- 1Y
- 32.61%
- 3Y*
- 9.42%
- 5Y*
- 1.30%
- 10Y*
- 7.19%
EEMA
- 1D
- 0.47%
- 1M
- 0.51%
- YTD
- 23.70%
- 6M
- 27.45%
- 1Y
- 44.66%
- 3Y*
- 22.04%
- 5Y*
- 6.58%
- 10Y*
- 10.78%
IBB vs. EEMA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
IBB iShares Nasdaq Biotechnology ETF | 1.19% | 27.98% | -2.41% | 3.76% | -13.69% | 0.95% | 26.01% | 25.42% | -9.53% | 21.08% |
EEMA iShares MSCI Emerging Markets Asia ETF | 23.70% | 33.27% | 10.23% | 6.57% | -21.49% | -4.22% | 25.17% | 18.60% | -15.76% | 43.41% |
Correlation
The correlation between IBB and EEMA is 0.39, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.39 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.42 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.47 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.47 |
Correlation (All Time) Calculated using the full available price history since Feb 9, 2012 | 0.44 |
IBB vs. EEMA - Sectors Allocation Comparison
Sectors
IBB
EEMA
Healthcare
Basic Materials
-
Communication Services
-
Consumer Cyclical
-
Consumer Defensive
-
Energy
-
Financial Services
-
Industrials
-
Real Estate
-
Technology
-
Utilities
-
Healthcare
IBB
EEMA
Basic Materials
IBB
-
EEMA
Communication Services
IBB
-
EEMA
Consumer Cyclical
IBB
-
EEMA
Consumer Defensive
IBB
-
EEMA
Energy
IBB
-
EEMA
Financial Services
IBB
-
EEMA
Industrials
IBB
-
EEMA
Real Estate
IBB
-
EEMA
Technology
IBB
-
EEMA
Utilities
IBB
-
EEMA
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
IBB vs. EEMA — Risk / Return Rank
IBB
EEMA
IBB vs. EEMA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq Biotechnology ETF (IBB) and iShares MSCI Emerging Markets Asia ETF (EEMA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| IBB | EEMA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.46 | ||
| Sortino ratioReturn per unit of downside risk | -0.38 | ||
| Omega ratioGain probability vs. loss probability | 1.27 | 1.39 | -0.11 |
| Calmar ratioReturn relative to maximum drawdown | 3.40 | 3.14 | +0.26 |
| Martin ratioReturn relative to average drawdown | 10.49 | 11.43 | -0.94 |
Loading charts...
Drawdowns
IBB vs. EEMA - Drawdown Comparison
The maximum IBB drawdown since its inception was -62.85%, which is greater than EEMA's maximum drawdown of -44.18%. Use the drawdown chart below to compare losses from any high point for IBB and EEMA.
Loading charts...
Drawdown Indicators
| IBB | EEMA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -62.85% | -44.18% | -18.67% |
Max Drawdown (1Y)Largest decline over 1 year | -9.63% | -14.30% | +4.67% |
Max Drawdown (3Y)Largest decline over 3 years | -24.85% | -20.23% | -4.62% |
Max Drawdown (5Y)Largest decline over 5 years | -39.82% | -40.46% | +0.64% |
Max Drawdown (10Y)Largest decline over 10 years | -39.82% | -44.18% | +4.36% |
Current DrawdownCurrent decline from peak | -3.86% | -4.33% | +0.47% |
Average DrawdownAverage peak-to-trough decline | -21.16% | -13.95% | -7.21% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.14% | 3.92% | -0.78% |
Volatility
IBB vs. EEMA - Volatility Comparison
The current volatility for iShares Nasdaq Biotechnology ETF (IBB) is 7.73%, while iShares MSCI Emerging Markets Asia ETF (EEMA) has a volatility of 10.16%. This indicates that IBB experiences smaller price fluctuations and is considered to be less risky than EEMA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| IBB | EEMA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.73% | 10.16% | -2.43% |
Volatility (6M)Calculated over the trailing 6-month period | 15.86% | 18.97% | -3.11% |
Volatility (1Y)Calculated over the trailing 1-year period | 20.35% | 21.67% | -1.32% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 22.00% | 20.66% | +1.34% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 23.23% | 20.97% | +2.26% |
IBB vs. EEMA - Expense Ratio Comparison
IBB has a 0.47% expense ratio, which is lower than EEMA's 0.50% expense ratio.
Dividends
IBB vs. EEMA - Dividend Comparison
IBB's dividend yield for the trailing twelve months is around 0.23%, less than EEMA's 1.19% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EEMA iShares MSCI Emerging Markets Asia ETF | 1.19% | 1.48% | 1.74% | 2.02% | 1.78% | 2.19% | 1.15% | 1.86% | 2.17% | 1.74% | 1.74% | 2.44% |
IBB iShares Nasdaq Biotechnology ETF | 0.23% | 0.23% | 0.29% | 0.26% | 0.31% | 0.21% | 0.21% | 0.33% | 0.20% | 0.30% | 0.19% | 0.03% |
Frequently Asked Questions
IBB and EEMA have a correlation of 0.39, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
EEMA has higher volatility (10.16%) compared to IBB (7.73%). In terms of maximum drawdown, IBB dropped -62.85% vs EEMA's -44.18%.
On 10-year performance, EEMA leads with 10.78% vs 7.19% for IBB. On fees, IBB is cheaper at 0.47% per year. On volatility, IBB has been the lower-risk option at 7.73%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 10-year period, EEMA has performed better with a 10.78% return vs 7.19%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
IBB is cheaper with a 0.47% expense ratio, compared with 0.50% for EEMA.
EEMA has the higher dividend yield at 1.19%, compared with 0.23% for IBB.
IBB is categorized as Health & Biotech Equities, while EEMA is Asia Pacific Equities. IBB tracks NASDAQ Biotechnology Index, while EEMA tracks MSCI Emerging Markets Asia Index. Their fees differ too: 0.47% for IBB and 0.50% for EEMA.
EEMA currently has the higher Sharpe Ratio (2.07 vs 1.61), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for IBB and EEMA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer